201 related articles for article (PubMed ID: 15177058)
1. Is there a connection between estrogen and Parkinson's disease?
Shulman LM
Parkinsonism Relat Disord; 2002 Jun; 8(5):289-95. PubMed ID: 15177058
[TBL] [Abstract][Full Text] [Related]
2. Estrogens and Parkinson's disease.
Session DR; Pearlstone MM; Jewelewicz R; Kelly AC
Med Hypotheses; 1994 Apr; 42(4):280-2. PubMed ID: 8072437
[TBL] [Abstract][Full Text] [Related]
3. Implications for estrogens in Parkinson's disease: an epidemiological approach.
Ragonese P; D'Amelio M; Savettieri G
Ann N Y Acad Sci; 2006 Nov; 1089():373-82. PubMed ID: 17261781
[TBL] [Abstract][Full Text] [Related]
4. Formulations of hormone therapy and risk of Parkinson's disease.
Lundin JI; Ton TG; LaCroix AZ; Longstreth WT; Franklin GM; Swanson PD; Smith-Weller T; Racette BA; Checkoway H
Mov Disord; 2014 Nov; 29(13):1631-6. PubMed ID: 25255692
[TBL] [Abstract][Full Text] [Related]
5. Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration.
Labandeira-Garcia JL; Rodriguez-Perez AI; Valenzuela R; Costa-Besada MA; Guerra MJ
Front Neuroendocrinol; 2016 Oct; 43():44-59. PubMed ID: 27693730
[TBL] [Abstract][Full Text] [Related]
6. A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease.
Parkinson Study Group POETRY Investigators
Parkinsonism Relat Disord; 2011 Dec; 17(10):757-60. PubMed ID: 21824799
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
Morissette M; Al Sweidi S; Callier S; Di Paolo T
Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001
[TBL] [Abstract][Full Text] [Related]
8. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and Parkinson's disease.
Kompoliti K
Front Biosci; 2003 May; 8():s391-400. PubMed ID: 12700049
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and movement disorders.
Kompoliti K
Clin Neuropharmacol; 1999; 22(6):318-26. PubMed ID: 10626091
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice.
Hwang CJ; Choi DY; Jung YY; Lee YJ; Yun JS; Oh KW; Han SB; Oh S; Park MH; Hong JT
Horm Behav; 2016 Apr; 80():19-29. PubMed ID: 26836768
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
13. [The role of estrogens in Parkinson's disease].
Dziedziejko V; Białecka M; Machoy-Mokrzyńska A; Kłodowska-Duda G; Chlubek D
Postepy Hig Med Dosw (Online); 2009 Dec; 63():627-33. PubMed ID: 20097949
[TBL] [Abstract][Full Text] [Related]
14. Effect of long-term estrogen therapy on dopaminergic responsivity in post-menopausal women--a preliminary study.
Craig MC; Cutter WJ; Wickham H; van Amelsvoort TA; Rymer J; Whitehead M; Murphy DG
Psychoneuroendocrinology; 2004 Nov; 29(10):1309-16. PubMed ID: 15288710
[TBL] [Abstract][Full Text] [Related]
15. Reproductive factors and Parkinson's disease: a multicenter case-control study.
Nicoletti A; Nicoletti G; Arabia G; Annesi G; De Mari M; Lamberti P; Grasso L; Marconi R; Epifanio A; Morgante L; Cozzolino A; Barone P; Quattrone A; Zappia M
Mov Disord; 2011 Dec; 26(14):2563-6. PubMed ID: 21956541
[TBL] [Abstract][Full Text] [Related]
16. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
Gambrell RD
Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
[TBL] [Abstract][Full Text] [Related]
17. Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats.
Rodriguez-Perez AI; Borrajo A; Valenzuela R; Lanciego JL; Labandeira-Garcia JL
Neurobiol Aging; 2015 Feb; 36(2):1194-208. PubMed ID: 25432430
[TBL] [Abstract][Full Text] [Related]
18. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease.
Gillies GE; Murray HE; Dexter D; McArthur S
Pharmacol Biochem Behav; 2004 Jul; 78(3):513-22. PubMed ID: 15251260
[TBL] [Abstract][Full Text] [Related]
19. Postmenopausal estrogen use affects risk for Parkinson disease.
Currie LJ; Harrison MB; Trugman JM; Bennett JP; Wooten GF
Arch Neurol; 2004 Jun; 61(6):886-8. PubMed ID: 15210525
[TBL] [Abstract][Full Text] [Related]
20. Neuroactive gonadal drugs for neuroprotection in male and female models of Parkinson's disease.
Litim N; Morissette M; Di Paolo T
Neurosci Biobehav Rev; 2016 Aug; 67():79-88. PubMed ID: 26708712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
